This co-targeting approach is particularly promising in tumors where both MAPK and PI3K pathways are activated.​ These findings underscore the importance of MAPK3 activation in breast cancer progression and the potential for MAPK pathway inhibitors like trametinib as viable treatment options (72). Here, MAPK3 is linked to breast carcinoma.